The Impact of Endocrine Therapy on Cognitive Functions of Breast Cancer Patients: A Systematic Review

2015 ◽  
Vol 36 (2) ◽  
pp. 109-118 ◽  
Author(s):  
Ioannis Bakoyiannis ◽  
Eleousa-Alexandra Tsigka ◽  
Despina Perrea ◽  
Vasilios Pergialiotis
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Cognitive Functions ◽  
Breast Cancer Patients ◽  
The Impact

Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients

2021 ◽  
Author(s):  
Siyi Zhu ◽  
Yiwei Tong ◽  
Weiguo Chen ◽  
Xiaosong Chen ◽  
Kunwei Shen
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Clinicopathological Characteristics ◽  
Obese Group ◽  
Treatment Modalities ◽  
Endocrine Treatment ◽  
Breast Cancer Patients ◽  
The Impact

Abstract Purpose Our purpose was to evaluate the influence of obesity on clinicopathological characteristics of breast cancer. Secondly we wanted to explore the effect of obesity on the performance of endocrine therapy in Chinese breast cancer patients. Methods Patients with luminal/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer were included and categorized into the non-obese (BMI < 28 kg/m²) and obese (BMI ≥ 28 kg/m²) groups according to body mass index (BMI). Clinicopathological characteristics and treatment modalities were compared among two groups. Furthermore, the interaction of adjuvant endocrine therapy and efficacy between non-obese and obese groups were analyzed. Results A total of 2875 patients were included: 2598 in the non-obese group and 277 in the obese group. A higher rate of patients with comorbidities (OR: 2.83, 95%CI 2.13–3.74, P < 0.001) or PR positive tumor (OR: 1.63, 95%CI 1.03–2.58, P = 0.037) were identified in the obese group. Obesity was not associated with disease recurrence (P = 0.839) or overall survival (P = 0.140) in the whole population. Subgroup analysis did show an association with worse relapse-free survival (RFS, HR 3.48, 95%CI 1.31–9.22, P = 0.012) and overall survival (OS, HR 4.67, 95%CI 1.28–16.95, P = 0.019) in luminal A breast cancer. These results could not be reproduced in the luminal B subtype with a RFS (HR 0.78, 95%CI 0.41–1.49, P = 0.454) or OS (HR 1.17, 95%CI 0.50–2.74, P = 0.727). Furthermore, obesity didn’t impact endocrine therapy effectiveness, neither in Tamoxifen nor aromatase inhibitor group (RFS: interact P = 0.381; OS: interact P = 0.888). Conclusion The impact of obesity on prognosis interacted with luminal subtype status in Chinese breast cancer patients, which was not related with endocrine treatment modality.

scholarly journals Training Cognitive Functions Using Mobile Apps in Breast Cancer Patients: Systematic Review

10.2196/10855 ◽  
2019 ◽  
Vol 7 (3) ◽  
pp. e10855 ◽  
Author(s):  
Laura Vergani ◽  
Giulia Marton ◽  
Silvia Francesca Maria Pizzoli ◽  
Dario Monzani ◽  
Ketti Mazzocco ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Cognitive Functions ◽  
Mobile Apps ◽  
Breast Cancer Patients

scholarly journals Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials

2019 ◽  
Vol 18 ◽  
pp. 100252 ◽  
Author(s):  
Antonio Galvano ◽  
Dalila Scaturro ◽  
Giuseppe Badalamenti ◽  
Lorena Incorvaia ◽  
Sergio Rizzo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Bone Health ◽  
Randomized Trials ◽  
Meta Analysis ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document